NCT06772480View on ClinicalTrials.gov

Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 5, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Liver CirrhosisGastric Antral Vascular Ectasia
Interventions
DRUG

Thalidomide

Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months

PROCEDURE

Argon Plasma Coagulation

Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06772480 - Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial) | Biotech Hunter | Biotech Hunter